Navigation Links
Oncolytics Biotech Inc. announces approval for UK clinical trial
Date:10/24/2007

CALGARY, AB, --- October 24, 2007 - Oncolytics Biotech Inc. (Oncolytics) (TSX:ONC, NASDAQ:ONCY) announced that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a clinical trial using intravenous administration of REOLYSIN® in combination with cyclophosphamide, a chemotherapeutic agent as well as immune modulator, in patients with advanced cancers. The Principal Investigators are Dr. James Spicer of Kings College in London, Dr. Johann de Bono and Dr. Kevin Harrington of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, and Professor Hardev Pandha of the Royal Surrey County Hospital NHS Trust, Surrey and Mount Alvernia Hospitals.

The Company also intends to host a conference call Wednesday, October 24, 2007 to provide an update on its expanding clinical program. The dial-in details appear below.

We are really looking forward to treating patients in this trial, said Principal Investigator Dr. James Spicer. The hope is that it will provide valuable information about the relationship between oncolytic viral therapy and the immune response of the patient.

The trial (REO 012) is an open-label, dose-escalating, non-randomized trial of REOLYSIN® given intravenously with escalating doses of cyclophosphamide. A standard dose of REOLYSIN® is administered intravenously over five consecutive days, while an intravenous dose of cyclophosphamide is administered three days before REOLYSIN® treatment and continues through the course of the treatment cycle. The total number of patients studied will depend on the number of dose levels tested, but it is anticipated to be approximately 30 patients.


'/>"/>

Contact: Cathy Ward
cathy.ward@oncolytics.ca
403-670-7370
Oncolytics Biotech Inc.
Source:Eurekalert

Page: 1

Related medicine news :

1. Biotechnology industry expected to grow into a three billion dollar industry by 2002
2. Biotechnology on the lead
3. Panacea Biotech To Market Anthrax Vaccine
4. Commercialization of Biotech Discoveries, An Encouragement For Researchers
5. Biotech drug causing anemia-EPREX
6. Leading Biotech Companies Are Interested In Acquisition Of Smaller Companies
7. Biologicals Transfer Proposal between US and Indian Biotechnology
8. Finland and India to interact and cooperate in the filed of telemedicine and biotechnology
9. Vical Biotech and NIH jointly develops HIV vaccine
10. Biotechnology Initiatives Planned In Hyderabad
11. Biotech Osiris to go public
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... Just in time for ... tasty, gluten-free chocolate chip cookie recipe for Honeyville’s new Organic Quinoa Flour product for ... branch out in the near future. , “I think it’s wonderful that a ...
(Date:12/6/2016)... ... December 06, 2016 , ... Keeping Gift Season Safe, In ... that are safe and age-appropriate for their recipients. This is the idea behind Safe ... the safety of items that would make good gifts for children. For companies that ...
(Date:12/6/2016)... ... 06, 2016 , ... "Add realistic flares and light leaks to your media ... to clip with high quality 4K lens flare footage," said Christina Austin - CEO ... filmed on the RED Dragon. Utilizing the Dragon Sensor, TransFlare 4K Jewel lens flare ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... transitional care facility – Avamere Transitional Care of Puget Sound ; located ... post-acute health care center will provide patients recovering from illness or injury with ...
(Date:12/5/2016)... ... December 05, 2016 , ... Worldwise ®, ... lifestyle design firm kathy ireland® Worldwide for five additional years, announced by Kevin ... an exclusive licensing agreement three years ago to design and develop the kathy ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016 Sanovas, Inc., ... accelerator, announced today the launch of its wholly owned subsidiary, ... Logo - http://photos.prnewswire.com/prnh/20161202/445250LOGO   Logo - http://photos.prnewswire.com/prnh/20161202/445251LOGO   ... ... There are ...
(Date:12/5/2016)... -- Wellbridge Health and Gateway Health proudly announce a dynamic collaboration ... Medicaid plan members with specific high risk needs. ... this group of consumers, Wellbridge combines technology and population expertise ... into members, daily behaviors and lifestyle. ... , , ...
(Date:12/5/2016)... 5, 2016  Recently Zymo Research announced an ... known as Horvath,s Clock. Based on this technology, ... service to academic and biopharma scientific researchers to ... other than sperm. The service quantifies ... age versus chronological age following drug treatments and ...
Breaking Medicine Technology: